PF-Atlas › Clinical Trials › NCT07344558

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

MNKD-201 · Phase 1

Registry ID

NCT07344558

Phase

Phase 1

Status

Recruiting

Drug / intervention

MNKD-201(Nintedanib DPI)

Sponsor

Mannkind Corporation

Start

2025-12-22

Enrollment

Locations

About this trial

MKC-NI-002 is a Phase 1b, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in patients with Idiopathic Pulmonary Fibrosis (IPF). The trial consists of Multiple Ascending Doses (MAD) with the primary objective to evaluate safety, tolerability and pharmacokinetics (PK) of MNKD-201 compared to placebo in patients with IPF.

View NCT07344558 on ClinicalTrials.gov →

Explore related

All MNKD-201 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT07344558 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.